Morgan Stanley Cuts Personalis (NASDAQ:PSNL) Price Target to $10.00

Personalis (NASDAQ:PSNL) had its target price lowered by Morgan Stanley from $11.00 to $10.00 in a research note published on Thursday morning,Benzinga reports. Morgan Stanley currently has an equal weight rating on the stock.

Several other brokerages have also recently commented on PSNL. Needham & Company LLC lifted their price target on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. HC Wainwright raised their price objective on shares of Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Lake Street Capital reaffirmed a “buy” rating and set a $11.00 target price on shares of Personalis in a report on Wednesday, November 5th. BTIG Research upped their target price on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Finally, Guggenheim increased their price target on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Personalis Stock Down 8.4%

PSNL stock opened at $7.84 on Thursday. Personalis has a twelve month low of $2.83 and a twelve month high of $11.50. The company has a market cap of $820.30 million, a P/E ratio of -8.62 and a beta of 2.02. The business has a fifty day moving average of $8.85 and a 200-day moving average of $8.12.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.05. The firm had revenue of $17.35 million during the quarter, compared to analyst estimates of $17.12 million. Personalis had a negative return on equity of 39.13% and a negative net margin of 116.69%. As a group, equities research analysts anticipate that Personalis will post -1.4 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Personalis

A number of hedge funds have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Personalis by 273.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company’s stock valued at $85,812,000 after purchasing an additional 7,896,714 shares in the last quarter. ARK Investment Management LLC increased its stake in Personalis by 11.3% during the 3rd quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock worth $51,574,000 after purchasing an additional 802,268 shares in the last quarter. AIGH Capital Management LLC raised its holdings in Personalis by 4.5% during the 3rd quarter. AIGH Capital Management LLC now owns 3,892,101 shares of the company’s stock worth $25,376,000 after buying an additional 168,143 shares during the period. Aberdeen Group plc raised its holdings in Personalis by 36.1% during the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after buying an additional 861,948 shares during the period. Finally, Kennedy Capital Management LLC lifted its stake in Personalis by 196.2% in the third quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after buying an additional 1,281,695 shares in the last quarter. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.